Document Detail

Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure.
MedLine Citation:
PMID:  16054474     Owner:  NLM     Status:  MEDLINE    
In this randomized, placebo-controlled study, it was found that a 24-hour levosimendan infusion improves echocardiographic markers of abnormal left ventricular diastolic function (transmitral flow patterns and mitral annulus velocities, as assessed by transthoracic pulse-wave Doppler and tissue Doppler imaging, respectively) and reduces substances of excessive neurohormonal activation (plasma B-type natriuretic peptide and interleukin-6) in patients with advanced heart failure. Moreover, levosimendan-treated patients had fewer events and longer progression-free survival during a 5-month follow-up compared with those who received placebo. Thus, levosimendan seems to be effective in improving left ventricular diastolic function and reducing neurohormonal activation in patients with severe heart failure.
John T Parissis; Fotios Panou; Dimitrios Farmakis; Stamatis Adamopoulos; Gerasimos Filippatos; Ioannis Paraskevaidis; Koula Venetsanou; John Lekakis; Dimitrios Th Kremastinos
Related Documents :
9703234 - Effect of loading conditions on myocardial relaxation velocities determined by doppler ...
18422674 - Echocardiographic diastolic dysfunction and magnetic resonance infarct size in healed m...
22052234 - The prognostic significance of coronary ct angiography.
22150844 - N-terminal pro-b-type natriuretic peptide is associated with severity of the coronary l...
11446504 - Combination of n-methyl-1-deoxynojirimycin and ischemic preconditioning markedly reduce...
19594814 - Impaired myocardial function in hypertrophic cardiomyopathy.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  The American journal of cardiology     Volume:  96     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2005 Aug 
Date Detail:
Created Date:  2005-08-01     Completed Date:  2005-09-13     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  423-6     Citation Subset:  AIM; IM    
Second Department of Cardiology and Heart Failure Clinic, Attikon University Hospital, Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiotonic Agents / administration & dosage,  therapeutic use*
Chi-Square Distribution
Echocardiography, Doppler
Heart Failure / blood*,  drug therapy*,  ultrasonography
Hydrazones / administration & dosage,  therapeutic use*
Infusions, Intravenous
Interleukin-6 / blood
Middle Aged
Natriuretic Peptide, Brain / blood
Pyridazines / administration & dosage,  therapeutic use*
Statistics, Nonparametric
Treatment Outcome
Ventricular Dysfunction, Left / blood*,  drug therapy*,  ultrasonography
Reg. No./Substance:
0/Cardiotonic Agents; 0/Hydrazones; 0/Interleukin-6; 0/Pyridazines; 114471-18-0/Natriuretic Peptide, Brain; 131741-08-7/simendan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparison of effectiveness of cardiac resynchronization therapy in patients <70 versus > or =70 yea...
Next Document:  Prognostic value of iodine-123-metaiodobenzylguanidine myocardial uptake and heart rate variability ...